Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Antengene Corporation Limited
  6. News
  7. Summary
    6996   KYG039571008

ANTENGENE CORPORATION LIMITED

(6996)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Antengene Corporation Limited Announces Executive Changes

06/18/2021 | 12:29am EDT

Antengene Corporation Limited announced that Mr. Yiteng Liu and Mr. Zhen Li has retired as an executive Director and a non-executive Director, respectively, at the conclusion of the AGM. Dr. Kevin Patrick Lynch and Mr. Donald Andrew Lung have been elected as executive Directors at the AGM with effect from June 18, 2021.


ę S&P Capital IQ 2021
All news about ANTENGENE CORPORATION LIMITED
09/15Antengene Selected as a Constituent of the FTSE Global Equity Index Series
DJ
09/03ANTENGENE : Cancer Treatment Gets Approval for Phase 1 Clinical Trial in Australia; Shares..
MT
08/23ANTENGENE : Gets Chinese Regulator Nod for Phase 2 Trial of Potential Myelofibrosis Treatm..
MT
08/23ANTENGENE : Announces Approval of the Phase II Study of Selinexor for the Treatment of Mye..
PR
08/23Antengene Corporation Limited Announces Approval of the Phase II Study of Selinexor for..
CI
08/23Antengene Narrows H1 Loss on Lower Research and Development Costs
MT
08/20Antengene Corporation Limited Announces Unaudited Consolidated Earnings Results for the..
CI
08/08Antengene Corporation Limited and MindRank AI Enter into Collaboration to Advance the D..
CI
08/02KARYOPHARM THERAPEUTICS : Partner Antengene Says Cancer Drug Xpovio Gets Approval in South..
MT
07/30ANTENGENE : Voluntary announcement approval of nda by the mfds for atg-010 (selinexor) for..
PU
More news
Financials
Sales 2021 2,00 M 0,31 M 0,31 M
Net income 2021 -752 M -116 M -116 M
Net cash 2021 3 307 M 511 M 511 M
P/E ratio 2021 -8,46x
Yield 2021 -
Capitalization 6 621 M 1 024 M 1 024 M
EV / Sales 2021 1 657x
EV / Sales 2022 23,2x
Nbr of Employees 219
Free-Float 56,2%
Chart ANTENGENE CORPORATION LIMITED
Duration : Period :
Antengene Corporation Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ANTENGENE CORPORATION LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 9,86 CNY
Average target price 22,02 CNY
Spread / Average Target 123%
EPS Revisions
Managers and Directors
Jian Ming Mei Chairman & Chief Executive Officer
Donald Andrew Lung Chief Financial Officer & Executive Director
Bo Shan Chief Scientific Officer
Kevin Lynch Executive Director & Chief Medical Officer
Yiteng Liu Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
ANTENGENE CORPORATION LIMITED-30.69%1 024
GILEAD SCIENCES, INC.23.12%89 936
BIONTECH SE318.73%82 443
WUXI APPTEC CO., LTD.35.75%69 407
REGENERON PHARMACEUTICALS33.91%67 262
VERTEX PHARMACEUTICALS-21.38%48 202